Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Icos Cialis Marketing Plan Will Target Four Million Former Viagra Users

Executive Summary

Marketing efforts for Lilly/Icos' pending erectile dysfunction treatment Cialis will target the approximately four million patients who have discontinued Pfizer's Viagra (sildenafil).

You may also be interested in...



Lilly Supports Cialis Spontaneity With Internet Trial, Direct Patient Data

Lilly's program to create a "spontaneity" advantage for its erectile dysfunction drug Cialis includes a Phase IIIb trial with direct patient observation reports from an electronic reporting system developed by the California clinical trials firm, 1747, Inc

Lilly Supports Cialis Spontaneity With Internet Trial, Direct Patient Data

Lilly's program to create a "spontaneity" advantage for its erectile dysfunction drug Cialis includes a Phase IIIb trial with direct patient observation reports from an electronic reporting system developed by the California clinical trials firm, 1747, Inc

Viagra vs. Cialis?

Twenty-four hour duration in erectile responsiveness for Lilly/Icos' Cialis "may or may not be a good thing...in light of the nitrate interaction" with phosphodiesterase inhibitors, McKinnell cautions. Meanwhile, Pfizer CEO acknowledges that Cialis' 16 minutes to onset of action "does appear to be maybe faster by one hour" than Viagra, but questions whether the difference is meaningful

Related Content

UsernamePublicRestriction

Register

PS038443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel